Novartis said the U.S. Food and Drug Administration (FDA) had approved its drug Ilaris to treat a serious form of childhood arthritis.
Ilaris inhibits interleukin-1 beta, excessive production of which plays a prominent role in certain inflammatory diseases, the company said.
The drug is the only approved treatment specifically for the condition that can be given as a monthly subcutaneous injection,
Novartis said.
Ilaris is also approved in the European Union for the treatment of refractory gouty arthritis, Novartis said.
© 2026 Thomson/Reuters. All rights reserved.